|
|
pSPreS2 |
|
Vaxjo ID |
343 |
|
Vaccine Adjuvant Name |
pSPreS2 |
|
Adjuvant VO ID |
VO_0005692
|
|
Description |
fusion protein adjuvant derived from HBV surface antigen that induces Th1 resopnse |
|
Stage of Development |
Research |
|
Host Species for Testing |
Mouse |
|
Components |
fusion gene of 501 bp fragment of S (sequence positions 326–826) and the 93 bp fragment of PreS2 (sequence positions 3190–3215, 1–67) |
|
Structure |
fusion gene of 501 bp fragment of S (sequence positions 326–826) and the 93 bp fragment of PreS2 (sequence positions 3190–3215, 1–67) |
|
Preparation |
S–PreS2 was synthesized using those two fragments (501 bp for S and 93 for PreS2) as template through overlapping extension PCR, and sub-cloned into the pVAX1 via Hind III and Kpn I to generate plasmid |
|
Function |
Type: microbial derivative vaccine adjuvant. Induces Th1-biased immune profile. significant production of IFN-γ and low levels of IL-4 or IL-10 in BALB/c mice |
| References |
Zhou et al., 2012: Zhou H, Min J, Zhao Q, Gu Q, Cong H, Li Y, He S. Protective immune response against Toxoplasma gondii elicited by a recombinant DNA vaccine with a novel genetic adjuvant. Vaccine. 2012; 30(10); 1800-1806. [PubMed: 22240340].
|
|
